Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Wheeler

Showing results (261-270 of 454) with videos related to

Pageof 46
Sort By:
Clinical Kidney Journal|November 12, 2025
Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL studyDavid C Wheeler, Kevin M Pantalone, Lixin Guo, et al.
The Lancet. Diabetes & Endocrinology|October 16, 2020
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trialMegumi Oshima, Brendon L Neuen, Meg J Jardine, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 27, 2022
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysisPhil McEwan, Rebecca Boyce, Juan Jose Garcia Sanchez, et al.
The Lancet. Diabetes & Endocrinology|October 7, 2021
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialNiels Jongs, Tom Greene, Glenn M Chertow, et al.
American Journal of Nephrology|October 11, 2018
Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline DataIain C Macdougall, Claire White, Stefan D Anker, et al.
Advances in Therapy|July 3, 2024
Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective CohortHiddo Heerspink, Stephen Nolan, Juan-Jesus Carrero, et al.
The Annals of Occupational Hygiene|December 6, 2014
Using hierarchical cluster models to systematically identify groups of jobs with similar occupational questionnaire response patterns to assist rule-based expert exposure assessment in population-based studiesMelissa C Friesen, Susan M Shortreed, David C Wheeler, et al.
Journal of the American Society of Nephrology : JASN|July 18, 2025
Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKDWisanne M Bakker, Hiddo J L Heerspink, Niels Jongs, et al.
American Heart Journal|February 17, 2024
Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and AlbuminuriaHiddo Jl Heerspink, Michele Provenzano, Priya Vart, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 11, 2024
The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysisPhil McEwan, Peter D Gabb, Jason A Davis, et al.
Pageof 46

Showing results (261-270 of 454) with videos related to

Sort By:
Pageof 46
Clinical Kidney Journal|November 12, 2025
Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL studyDavid C Wheeler, Kevin M Pantalone, Lixin Guo, et al.
The Lancet. Diabetes & Endocrinology|October 16, 2020
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trialMegumi Oshima, Brendon L Neuen, Meg J Jardine, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 27, 2022
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysisPhil McEwan, Rebecca Boyce, Juan Jose Garcia Sanchez, et al.
The Lancet. Diabetes & Endocrinology|October 7, 2021
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialNiels Jongs, Tom Greene, Glenn M Chertow, et al.
American Journal of Nephrology|October 11, 2018
Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline DataIain C Macdougall, Claire White, Stefan D Anker, et al.
Advances in Therapy|July 3, 2024
Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective CohortHiddo Heerspink, Stephen Nolan, Juan-Jesus Carrero, et al.
The Annals of Occupational Hygiene|December 6, 2014
Using hierarchical cluster models to systematically identify groups of jobs with similar occupational questionnaire response patterns to assist rule-based expert exposure assessment in population-based studiesMelissa C Friesen, Susan M Shortreed, David C Wheeler, et al.
Journal of the American Society of Nephrology : JASN|July 18, 2025
Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKDWisanne M Bakker, Hiddo J L Heerspink, Niels Jongs, et al.
American Heart Journal|February 17, 2024
Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and AlbuminuriaHiddo Jl Heerspink, Michele Provenzano, Priya Vart, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 11, 2024
The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysisPhil McEwan, Peter D Gabb, Jason A Davis, et al.
Pageof 46